Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Myovant/Pfizer Launch Myfembree With An Emphasis On Building Uterine Fibroid Awareness

Executive Summary

Myovant CEO David Marek talked to Scrip about why the companies believe patients and physicians will choose Myfembree over AbbVie's Oriahnn.

You may also be interested in...



Myovant Expects Gradual Growth For Myfembree With Endometriosis Approval

Myovant and partner Pfizer have expected a slow ramp for Myfembree in uterine fibroids and new indication endometriosis as they build awareness and grow the market for the GnRH antagonist class.

Myovant's Next Act: Commercial Execution And Business Development

The company is ramping up the launches of Orgovyx for prostate cancer and Myfembree for uterine fibroids, including indication and geographic expansions, and evaluating business development opportunities.

Organon Is Serious About Building A Women's Health Company, Deal By Deal

CEO Kevin Ali talked to Scrip about his plans for Organon, ahead of the spinout from Merck & Co. Women's health will be the top priority. 

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC144432

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel